Remodeling the TIME by decreasing the proportion of TIBs, enhancing the infiltration of CD8+/CD4+ T cells, and inhibiting the proliferation of Treg cells, as well as increasing the secretion of IL‐2 and IFN‐γ and decreasing the secretion of IL‐10, IL‐4, and TGF‐β, could improve cancer immunotherapy efficiency.36 The gene discussed is CD8A; the disease is cancer.